[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-001", "question": "A 26-year-old G2P1 at 30 weeks' gestation presents with new-onset severe occipital headache, visual scotomata, and right upper quadrant pain. BP is 168/108 mmHg, HR 88, reflexes 3+ with 1-2 beats of clonus. Fetal heart tracing is category I. Labs: platelets 86,000/µL, AST 145 U/L, ALT 162 U/L, creatinine 0.9 mg/dL, urine protein/creatinine ratio 0.5. She received 10 mg IV hydralazine in triage 20 minutes ago; current BP is 162/104 mmHg. She desires future fertility and vaginal delivery if safe. What is the most appropriate NEXT step in management?", "options": ["Administer IV labetalol now and plan for induction of labor at 34 weeks", "Initiate magnesium sulfate and proceed with immediate induction of labor", "Initiate magnesium sulfate and administer betamethasone; plan delivery within 24 hours", "Administer additional IV hydralazine and observe; defer delivery until 34 weeks if blood pressure controlled", "Start oral labetalol and discharge with close outpatient follow-up and twice-weekly NSTs"], "answer": "C", "answer_index": 2, "explanation": "She has preeclampsia with severe features and evolving HELLP (thrombocytopenia, RUQ pain, transaminitis) at 30 weeks. For severe features <34 weeks, optimal care is magnesium, corticosteroids, and expedited delivery within 24 hours at a tertiary center, not expectant management. Immediate induction ignores steroid window and maternal stability; outpatient or prolonged expectant management is unsafe given platelets <100,000 and worsening symptoms.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a patient with HELLP syndrome (platelets <100,000/µL, elevated LFTs, RUQ pain) and severe preeclampsia (severe hypertension, CNS symptoms) at 30 weeks. According to ACOG guidelines, the management of HELLP syndrome at <34 weeks involves maternal stabilization (magnesium sulfate for seizure prophylaxis, antihypertensives) and expedited delivery. However, if maternal and fetal status are stable (Category I tracing, no eclampsia, abruption, or DIC), delivery should be delayed for 24–48 hours to administer a course of corticosteroids for fetal lung maturity. Option C correctly identifies the need for magnesium, corticosteroids, and a plan for delivery within a short timeframe (expedited but allowing for steroid benefit). Option B is incorrect because immediate induction without steroids ignores the benefit of fetal lung maturity in a stable fetus. Options A and D are incorrect because expectant management until 34 weeks is contraindicated in HELLP syndrome or severe preeclampsia with worsening end-organ dysfunction (platelets <100k, persistent CNS symptoms). Option E is unsafe. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a patient with HELLP syndrome (platelets <100,000/µL, elevated LFTs, RUQ pain) and severe preeclampsia (severe hypertension, CNS symptoms) at 30 weeks. According to ACOG guidelines, the management of HELLP syndrome at <34 weeks involves maternal stabilization (magnesium sulfate for seizure prophylaxis, antihypertensives) and expedited delivery. However, if maternal and fetal status are stable (Category I tracing, no eclampsia, abruption, or DIC), delivery should be delayed for 24–48 hours to administer a course of corticosteroids for fetal lung maturity. Option C correctly identifies the need for magnesium, corticosteroids, and a plan for delivery within a short timeframe (expedited but allowing for steroid benefit). Option B is incorrect because immediate induction without steroids ignores the benefit of fetal lung maturity in a stable fetus. Options A and D are incorrect because expectant management until 34 weeks is contraindicated in HELLP syndrome or severe preeclampsia with worsening end-organ dysfunction (platelets <100k, persistent CNS symptoms). Option E is unsafe. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-002", "question": "A 58-year-old man with ischemic cardiomyopathy (LVEF 20%), CRT-D in place, and NYHA class III symptoms despite optimal GDMT (sacubitril/valsartan, carvedilol, spironolactone, empagliflozin, loop diuretic) presents with weight gain and dyspnea. BP 104/66 mmHg, HR 72 (biventricular paced), JVP 12 cm, bibasilar crackles, moderate ascites, no peripheral edema. Labs: Na 130 mEq/L, K 4.4, creatinine 1.8 (baseline 1.3), NT-proBNP 12,000 pg/mL. Echo: LVEF 20%, severe functional MR, normal RV size, mildly reduced RV function, PASP 55 mmHg. Right heart cath: RAP 18 mmHg, PCWP 32 mmHg, CI 1.7 L/min/m², SVR 2100 dyn·s/cm⁵. After IV diuresis, he remains hypotensive with CI 1.6. He is INTERMACS profile 4. What is the best definitive next step?", "options": ["Add continuous IV milrinone as palliative inotropic therapy without advanced therapies", "Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge", "Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR", "Refer for durable LVAD implantation as bridge to transplant or destination therapy", "Implant a percutaneous Impella device as bridge to decision in the ICU"], "answer": "D", "answer_index": 3, "explanation": "He has advanced, stage D HFrEF with persistent low-output symptoms, high filling pressures, and INTERMACS profile 4, making him appropriate for durable LVAD as bridge to transplant or destination. Isolated transplant without LVAD is not ideal given instability; TEER is for less advanced, stable patients. Chronic inotropes or short-term MCS alone are not definitive strategies in a transplant/LVAD candidate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The patient presents with Stage D HFrEF, characterized by low cardiac output (CI 1.6 L/min/m²), congestion (PCWP 32 mmHg), and worsening renal function (cardiorenal syndrome), classified as INTERMACS 4. The best definitive next step is referral for durable LVAD (Option D). LVAD is the standard of care for eligible INTERMACS 3–4 patients, serving as a bridge to transplant or destination therapy, and will address the low output and secondary MR by unloading the LV. Option A is incorrect because there is no evidence the patient is ineligible for advanced therapies. Option B is incorrect; under current UNOS allocation, Status 2 requires active mechanical support (e.g., IABP, Impella), which the patient does not have, and listing alone does not address the immediate hemodynamic inadequacy. Option C (TEER) is typically reserved for patients who are stable on GDMT; this patient has low-output failure requiring flow restoration, which TEER may not sufficiently provide. Option E is for acute cardiogenic shock (INTERMACS 1–2), whereas this patient is in a subacute deteriorating phase suitable for durable support. A minor stem flaw exists: initial BP is 104/66 (normotensive), but the text later states he \\\"remains hypotensive\\\" after diuresis without providing a new value; however, the low CI confirms the low-output state, making the item solvable.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The patient presents with Stage D HFrEF, characterized by low cardiac output (CI 1.6 L/min/m²), congestion (PCWP 32 mmHg), and worsening renal function (cardiorenal syndrome), classified as INTERMACS 4. The best definitive next step is referral for durable LVAD (Option D). LVAD is the standard of care for eligible INTERMACS 3–4 patients, serving as a bridge to transplant or destination therapy, and will address the low output and secondary MR by unloading the LV. Option A is incorrect because there is no evidence the patient is ineligible for advanced therapies. Option B is incorrect; under current UNOS allocation, Status 2 requires active mechanical support (e.g., IABP, Impella), which the patient does not have, and listing alone does not address the immediate hemodynamic inadequacy. Option C (TEER) is typically reserved for patients who are stable on GDMT; this patient has low-output failure requiring flow restoration, which TEER may not sufficiently provide. Option E is for acute cardiogenic shock (INTERMACS 1–2), whereas this patient is in a subacute deteriorating phase suitable for durable support. A minor stem flaw exists: initial BP is 104/66 (normotensive), but the text later states he \"remains hypotensive\" after diuresis without providing a new value; however, the low CI confirms the low-output state, making the item solvable.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-003", "question": "A previously healthy 4-year-old boy presents with 10 days of fever to 39.5°C, conjunctival injection without exudate, cracked lips, polymorphous trunk rash, edema and erythema of hands and feet, and cervical lymphadenopathy. Symptoms partially improved after ibuprofen but recur when stopped. Day-10 echocardiogram: diffuse coronary artery ectasia with z-scores 2.3-2.7, mild LV dysfunction (EF 50%), and small pericardial effusion. Labs: WBC 14,000/µL, platelets 520,000/µL, CRP 10 mg/dL, ESR 80 mm/hr, ALT mildly elevated, sterile pyuria. COVID serology and respiratory viral panel are negative. He has not yet received IVIG. What is the most appropriate initial treatment strategy now?", "options": ["Single dose IVIG 2 g/kg plus high-dose aspirin only", "IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg", "IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg", "IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day", "High-dose aspirin alone because presentation is after day 10 of illness"], "answer": "B", "answer_index": 1, "explanation": "He has classic Kawasaki disease with coronary changes and delayed presentation, which confers high risk of IVIG resistance and coronary progression. Current risk-adapted approaches favor adjunctive corticosteroids with IVIG in high-risk patients (coronary involvement and very elevated inflammatory markers), even after day 10. Aspirin monotherapy is inadequate; biologics are reserved for IVIG-resistant disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with Kawasaki Disease (KD) presenting with high-risk features: delayed diagnosis (Day 10), established coronary artery abnormalities (z-scores >2.5 indicate small aneurysms), and left ventricular dysfunction. While IVIG plus aspirin (Option A) is the standard primary therapy for unselected or low-risk KD, current guidelines (e.g., AHA 2017) and expert consensus support the use of adjunctive therapy—most commonly corticosteroids—for patients with baseline coronary artery aneurysms, cardiac dysfunction, or high risk of IVIG resistance. Therefore, adding methylprednisolone (Option B) is the most appropriate strategy to reduce the risk of progression. Option E is incorrect because treatment is indicated after Day 10 if there is ongoing inflammation or coronary pathology, both of which are present. Options C (infliximab) and D (anakinra) are generally reserved for IVIG-resistant disease or specific research protocols, whereas corticosteroids are the standard choice for initial intensification. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with Kawasaki Disease (KD) presenting with high-risk features: delayed diagnosis (Day 10), established coronary artery abnormalities (z-scores >2.5 indicate small aneurysms), and left ventricular dysfunction. While IVIG plus aspirin (Option A) is the standard primary therapy for unselected or low-risk KD, current guidelines (e.g., AHA 2017) and expert consensus support the use of adjunctive therapy—most commonly corticosteroids—for patients with baseline coronary artery aneurysms, cardiac dysfunction, or high risk of IVIG resistance. Therefore, adding methylprednisolone (Option B) is the most appropriate strategy to reduce the risk of progression. Option E is incorrect because treatment is indicated after Day 10 if there is ongoing inflammation or coronary pathology, both of which are present. Options C (infliximab) and D (anakinra) are generally reserved for IVIG-resistant disease or specific research protocols, whereas corticosteroids are the standard choice for initial intensification. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-004", "question": "A 32-year-old woman with mixed connective tissue disease (U1-RNP positive) on mycophenolate mofetil and low-dose prednisone presents with 3 months of progressive exertional dyspnea and near-syncope. Exam: loud P2, right ventricular heave, no crackles, no edema. HR 94, BP 108/68 mmHg, O2 sat 95% on room air. CT chest: no interstitial lung disease, no PE. TTE: normal LV, moderately dilated RV with reduced function, estimated PASP 75 mmHg, no shunt. Right heart cath: mPAP 46 mmHg, PAOP 9 mmHg, CI 2.0 L/min/m², PVR 9 Wood units. Autoantibodies: strong anti-U1-RNP, negative anti-Scl-70. She desires pregnancy within 1-2 years. What is the most appropriate initial advanced therapy strategy for her pulmonary hypertension?", "options": ["Start amlodipine after acute vasoreactivity testing, then titrate based on BP", "Initiate dual oral therapy with ambrisentan and tadalafil", "Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor", "Start inhaled treprostinil monotherapy and observe functional response", "Use riociguat monotherapy given connective tissue disease-associated PAH"], "answer": "C", "answer_index": 2, "explanation": "She has high-risk WHO group 1 CTD-associated PAH (RV dysfunction, mPAP 46, CI 2.0, PVR 9) and plans pregnancy (a major risk), warranting aggressive up-front therapy. Modern guidelines recommend initial triple therapy with parenteral prostacyclin in high-risk PAH patients. CCBs are only for acute vasoreactivity responders; dual or single oral agents are insufficient for this profile.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with Mixed Connective Tissue Disease (MCTD) and newly diagnosed WHO Group 1 Pulmonary Arterial Hypertension (PAH). Key prognostic markers include 'near-syncope' (a red flag for low cardiac output), physical exam findings of right ventricular (RV) failure (heave), echocardiographic evidence of RV dysfunction, and a low Cardiac Index (2.0 L/min/m²) on catheterization. These findings classify her as high-risk according to ESC/ERS guidelines. The standard of care for high-risk PAH is initial triple combination therapy including a parenteral prostacyclin (e.g., IV epoprostenol). Option C correctly identifies this strategy. Option A is incorrect because calcium channel blockers are indicated only for the small minority of patients with a positive acute vasoreactivity test (rare in CTD-PAH) and are dangerous in patients with low cardiac index/RV failure. Option B (dual oral therapy) is appropriate for intermediate-risk patients but insufficient for high-risk presentation. Options D and E (monotherapy) are inadequate for this severity. While the patient desires pregnancy, her high-risk status requires immediate aggressive therapy to prevent mortality; additionally, pregnancy is contraindicated in uncontrolled PAH. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with Mixed Connective Tissue Disease (MCTD) and newly diagnosed WHO Group 1 Pulmonary Arterial Hypertension (PAH). Key prognostic markers include 'near-syncope' (a red flag for low cardiac output), physical exam findings of right ventricular (RV) failure (heave), echocardiographic evidence of RV dysfunction, and a low Cardiac Index (2.0 L/min/m²) on catheterization. These findings classify her as high-risk according to ESC/ERS guidelines. The standard of care for high-risk PAH is initial triple combination therapy including a parenteral prostacyclin (e.g., IV epoprostenol). Option C correctly identifies this strategy. Option A is incorrect because calcium channel blockers are indicated only for the small minority of patients with a positive acute vasoreactivity test (rare in CTD-PAH) and are dangerous in patients with low cardiac index/RV failure. Option B (dual oral therapy) is appropriate for intermediate-risk patients but insufficient for high-risk presentation. Options D and E (monotherapy) are inadequate for this severity. While the patient desires pregnancy, her high-risk status requires immediate aggressive therapy to prevent mortality; additionally, pregnancy is contraindicated in uncontrolled PAH. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-005", "question": "A 24-year-old primigravida at 11 weeks presents with severe nausea, non-bloody emesis 10-15 times daily, 4-kg weight loss, orthostatic tachycardia, and inability to keep down oral medications despite pyridoxine/doxylamine and rectal promethazine. She has ketonuria, Na 131 mEq/L, K 2.9 mEq/L, bicarbonate 19 mEq/L, ALT 78 U/L, AST 65 U/L, normal lipase and thyroid function. Ultrasound: single viable intrauterine pregnancy. She requests to avoid hospitalization if possible and is anxious about teratogenic risk. What is the most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion?", "options": ["Start oral ondansetron and allow discharge with close outpatient follow-up", "Begin continuous subcutaneous metoclopramide infusion as an outpatient", "Administer IV ondansetron and admit for parenteral nutrition via PICC line", "Start transdermal scopolamine and oral mirtazapine", "Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital"], "answer": "E", "answer_index": 4, "explanation": "She has hyperemesis gravidarum with significant volume depletion and electrolyte derangements, requiring inpatient care and parenteral antiemetics. Phenothiazines (e.g., IV chlorpromazine) followed by scheduled IV ondansetron or metoclopramide are evidence-based for refractory hyperemesis. Outpatient oral or SC regimens are inappropriate given inability to tolerate PO; TPN is reserved for failure of intensive antiemetic therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes severe hyperemesis gravidarum (HG) with significant complications: orthostatic tachycardia, hypokalemia (K 2.9), and starvation ketosis. The patient has failed outpatient management (oral/rectal antiemetics). \\n\\n1.  **Triage:** The presence of hemodynamic instability (orthostasis) and severe electrolyte derangement mandates inpatient admission for IV fluid resuscitation and parenteral antiemetics. This immediately rules out Options A (oral/discharge) and B (outpatient pump), as discharge is unsafe.\\n2.  **Pharmacology/Management:** Option D relies on oral/transdermal routes which are insufficient for acute stabilization. This leaves Options C and E.\\n3.  **Discrimination:** Option C suggests admission but couples it with Total Parenteral Nutrition (TPN) via PICC. TPN is a last-resort therapy for HG, reserved for patients who fail IV antiemetics and enteral feeding; initiating it as a 'next step' is medically inappropriate and risky. Option E correctly identifies the need for admission and IV antiemetics. While chlorpromazine is often a third-line agent, its use in a refractory patient (failed promethazine) is evidence-based, and the option describes a safe inpatient induction followed by maintenance therapy. Despite the patient's preference to avoid admission, the medical severity overrides this request.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes severe hyperemesis gravidarum (HG) with significant complications: orthostatic tachycardia, hypokalemia (K 2.9), and starvation ketosis. The patient has failed outpatient management (oral/rectal antiemetics). \n\n1.  **Triage:** The presence of hemodynamic instability (orthostasis) and severe electrolyte derangement mandates inpatient admission for IV fluid resuscitation and parenteral antiemetics. This immediately rules out Options A (oral/discharge) and B (outpatient pump), as discharge is unsafe.\n2.  **Pharmacology/Management:** Option D relies on oral/transdermal routes which are insufficient for acute stabilization. This leaves Options C and E.\n3.  **Discrimination:** Option C suggests admission but couples it with Total Parenteral Nutrition (TPN) via PICC. TPN is a last-resort therapy for HG, reserved for patients who fail IV antiemetics and enteral feeding; initiating it as a 'next step' is medically inappropriate and risky. Option E correctly identifies the need for admission and IV antiemetics. While chlorpromazine is often a third-line agent, its use in a refractory patient (failed promethazine) is evidence-based, and the option describes a safe inpatient induction followed by maintenance therapy. Despite the patient's preference to avoid admission, the medical severity overrides this request.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-006", "question": "A 17-year-old previously healthy boy is admitted to the ICU with septic shock due to meningococcemia, requiring norepinephrine and mechanical ventilation. On day 4, BP stabilizes and pressors are stopped. Over the next 24 hours, he develops rapidly worsening hypoxemia with PaO2/FiO2 ratio 90, diffuse bilateral infiltrates, and new hemoptysis. Hb drops from 11 to 8 g/dL without obvious bleeding. Platelets are 220,000/µL, PT/INR normal, PTT normal, fibrinogen 400 mg/dL. Urinalysis: 3+ blood, 2+ protein, many dysmorphic RBCs. Creatinine rises from 0.8 to 2.1 mg/dL. ANA negative, ANCA panel negative, complements normal. Bronchoscopy shows diffuse alveolar hemorrhage; cultures pending. What is the most appropriate next step in management?", "options": ["High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis", "Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology", "Supportive care only, assuming septic coagulopathy-related lung injury", "Kidney biopsy as soon as feasible to guide immunosuppression decisions", "Start rituximab and prednisone for suspected immune-complex GN related to sepsis"], "answer": "D", "answer_index": 3, "explanation": "He has a pulmonary-renal syndrome with DAH and GN but negative ANCA/anti-GBM serologies and preserved platelets/coagulation, making pure septic DIC unlikely. In this critically ill patient, tissue diagnosis is essential before committing to aggressive immunosuppression, especially with negative serologies. Early kidney biopsy best clarifies the etiology; empiric cytotoxic therapy or plasmapheresis without diagnosis carries high risk and may be inappropriate if the lesion is infection-related.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with pulmonary-renal syndrome (DAH and GN) shortly after meningococcemia. The keyed answer (D, Kidney biopsy) is medically sound in principle; distinguishing infection-associated GN (requiring supportive care) from ANCA-negative vasculitis (requiring immunosuppression) is critical, and empiric cytotoxic therapy is dangerous in a post-septic patient. However, the item is logically underspecified (U). The stem reports \\\"ANCA panel negative\\\" but fails to explicitly state the status of anti-GBM antibodies. The provided rationale justifies the key by citing \\\"negative ANCA/anti-GBM serologies.\\\" Without knowing the anti-GBM status, Option B (Plasmapheresis for suspected anti-GBM) is a strong defensible choice for life-threatening DAH pending diagnosis. The exclusion of Option B relies on a fact (negative anti-GBM) that exists in the author's rationale but is absent from the vignette. While Option B's phrasing (\\\"despite negative serology\\\") hints at the status, it is ambiguous whether this establishes the fact or describes a hypothetical. To ensure a unique best answer, the stem must explicitly state \\\"anti-GBM antibodies are negative.\\\"\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with pulmonary-renal syndrome (DAH and GN) shortly after meningococcemia. The keyed answer (D, Kidney biopsy) is medically sound in principle; distinguishing infection-associated GN (requiring supportive care) from ANCA-negative vasculitis (requiring immunosuppression) is critical, and empiric cytotoxic therapy is dangerous in a post-septic patient. However, the item is logically underspecified (U). The stem reports \"ANCA panel negative\" but fails to explicitly state the status of anti-GBM antibodies. The provided rationale justifies the key by citing \"negative ANCA/anti-GBM serologies.\" Without knowing the anti-GBM status, Option B (Plasmapheresis for suspected anti-GBM) is a strong defensible choice for life-threatening DAH pending diagnosis. The exclusion of Option B relies on a fact (negative anti-GBM) that exists in the author's rationale but is absent from the vignette. While Option B's phrasing (\"despite negative serology\") hints at the status, it is ambiguous whether this establishes the fact or describes a hypothetical. To ensure a unique best answer, the stem must explicitly state \"anti-GBM antibodies are negative.\"", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-007", "question": "A 6-week-old full-term girl presents with poor feeding, tachypnea, and sweating with feeds. Weight is at the 3rd percentile (previously 40th). Vitals: HR 180, RR 60, BP 70/40 mmHg in all extremities, O2 sat 96% RA. Exam: hepatomegaly, gallop rhythm, 2/6 holosystolic murmur at apex radiating to axilla, no differential pulses. CXR: cardiomegaly, pulmonary overcirculation. Echo: dilated LV with EF 20%, moderate MR, normal coronaries, no coarctation or structural shunt, normal RV function. ECG: sinus tachycardia. Blood and viral studies pending. After starting IV milrinone and diuretics, she stabilizes. What is the MOST appropriate next step in definitive management planning?", "options": ["Discontinue inotropes as soon as EF improves above 35% and transition to oral heart failure therapy only", "Urgently list for heart transplant as status 1A given high mortality of infantile dilated cardiomyopathy", "Begin high-dose IVIG for presumed viral myocarditis and defer consideration of mechanical support", "Evaluate for durable LVAD candidacy as bridge to transplant or recovery", "Schedule elective mitral valve repair to reduce regurgitation and improve LV function"], "answer": "D", "answer_index": 3, "explanation": "She has severe idiopathic/viral dilated cardiomyopathy with EF 20% and inotrope dependence, placing her at high risk of deterioration. Early evaluation for durable LVAD as bridge to transplant or recovery is recommended in infants with advanced heart failure who respond incompletely to medical therapy. Immediate transplant listing without MCS may be risky given wait times; valve surgery will not address primary LV dysfunction; IVIG alone is insufficient as definitive strategy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a 6-week-old infant with severe dilated cardiomyopathy (EF 20%), likely secondary to myocarditis or idiopathic causes, who has stabilized on inotropes. The question asks for the most appropriate next step in definitive management planning. Option A (transition to orals only) is insufficient because, despite stabilization, the risk of decompensation is high, and a 'Plan B' (advanced therapy) must be established. Option C is incorrect because deferring consideration of mechanical support is unsafe in severe heart failure. Option E is incorrect as the mitral regurgitation is functional; valve surgery does not address the underlying muscle failure. The choice lies between B (urgent transplant listing) and D (VAD evaluation). Option D is the best answer because durable VADs (e.g., Berlin Heart) in infants are a critical strategy serving as a 'bridge to transplant' or 'bridge to recovery' (allowing myocardial rest). Given the high waitlist mortality and the potential for native heart recovery in myocarditis, evaluating for VAD candidacy is the most robust planning step. Option B is less optimal as a standalone 'next step' because 'Status 1A' criteria are specific and wait times are prohibitive without a bridging strategy. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a 6-week-old infant with severe dilated cardiomyopathy (EF 20%), likely secondary to myocarditis or idiopathic causes, who has stabilized on inotropes. The question asks for the most appropriate next step in definitive management planning. Option A (transition to orals only) is insufficient because, despite stabilization, the risk of decompensation is high, and a 'Plan B' (advanced therapy) must be established. Option C is incorrect because deferring consideration of mechanical support is unsafe in severe heart failure. Option E is incorrect as the mitral regurgitation is functional; valve surgery does not address the underlying muscle failure. The choice lies between B (urgent transplant listing) and D (VAD evaluation). Option D is the best answer because durable VADs (e.g., Berlin Heart) in infants are a critical strategy serving as a 'bridge to transplant' or 'bridge to recovery' (allowing myocardial rest). Given the high waitlist mortality and the potential for native heart recovery in myocarditis, evaluating for VAD candidacy is the most robust planning step. Option B is less optimal as a standalone 'next step' because 'Status 1A' criteria are specific and wait times are prohibitive without a bridging strategy. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-008", "question": "A 29-year-old woman at 36+1 weeks with known SLE (class IV lupus nephritis in remission on azathioprine and hydroxychloroquine) presents with 3 days of severe frontal headache, visual blurring, and increasing lower extremity edema. BP 164/102 mmHg (baseline 110/70), HR 92. Labs: platelets 185,000/µL, AST 40 U/L, ALT 35 U/L, creatinine 1.3 mg/dL (baseline 1.1), urine protein/creatinine ratio 2.2 (baseline 1.8), C3 and C4 low, anti-dsDNA titer increased from 1:80 to 1:320, urinalysis with active sediment (RBC casts). Fetus is cephalic, reassuring NST. What is the most appropriate management strategy?", "options": ["Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery", "Increase azathioprine dose and schedule induction at 39 weeks if no further worsening", "Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring", "Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks", "Add IV cyclophosphamide for nephritis flare and plan delivery after disease control"], "answer": "C", "answer_index": 2, "explanation": "She has overlapping features but labs favor SLE flare: rising dsDNA, low complement, active urinary sediment with only mild new proteinuria and preserved platelets/LFTs. At 36 weeks, severe preeclampsia would typically show worsening proteinuria and other end-organ features. Pulse steroids for lupus nephritis flare while continuing pregnancy with close monitoring is appropriate; immediate delivery is not mandatory unless maternal or fetal status deteriorates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: N (No answer defensible). Verdict on keyed answer: Medically unsafe. Key stem clues: 36 weeks gestation, BP 164/102, severe headache/visual blurring (severe features), RBC casts/low complement (active lupus nephritis). Main logical/medical issue: The patient presents with severe hypertension and end-organ neurological signs at 36 weeks. Regardless of whether the etiology is Preeclampsia or SLE Flare, the standard of care for severe features at this gestation is stabilization and delivery to prevent maternal mortality (stroke/eclampsia). Option C (Key) correctly identifies the nephritis flare but dangerously advises 'continuing pregnancy,' which violates safety standards. Option A correctly advises delivery but forces a diagnosis of 'superimposed preeclampsia' (ignoring the specific nephritis evidence) and omits necessary steroid treatment. No option offers the correct combined management: 'Administer steroids and proceed to delivery.' Minimal fix: Change Option C to 'Administer IV methylprednisolone and proceed to delivery.'\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: N (No answer defensible). Verdict on keyed answer: Medically unsafe. Key stem clues: 36 weeks gestation, BP 164/102, severe headache/visual blurring (severe features), RBC casts/low complement (active lupus nephritis). Main logical/medical issue: The patient presents with severe hypertension and end-organ neurological signs at 36 weeks. Regardless of whether the etiology is Preeclampsia or SLE Flare, the standard of care for severe features at this gestation is stabilization and delivery to prevent maternal mortality (stroke/eclampsia). Option C (Key) correctly identifies the nephritis flare but dangerously advises 'continuing pregnancy,' which violates safety standards. Option A correctly advises delivery but forces a diagnosis of 'superimposed preeclampsia' (ignoring the specific nephritis evidence) and omits necessary steroid treatment. No option offers the correct combined management: 'Administer steroids and proceed to delivery.' Minimal fix: Change Option C to 'Administer IV methylprednisolone and proceed to delivery.'", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-009", "question": "An intubated 65-year-old woman with severe influenza A pneumonia develops refractory hypoxemia despite lung-protective ventilation (TV 6 mL/kg, PEEP 14 cm H2O, FiO2 0.9) and paralysis. PaO2/FiO2 ratio is 70. She is placed on prone positioning for 16 hours/day with transient improvement but remains PaO2/FiO2 <80. Hemodynamics: MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L. No significant comorbidities; BMI 30 kg/m². Family consents to aggressive support. The center has on-site ECMO with experienced team but limited capacity. Which of the following is the most appropriate next step?", "options": ["Increase PEEP to 20 cm H2O and accept permissive hypercapnia before considering ECMO", "Initiate venovenous ECMO now due to refractory severe ARDS despite optimal conventional therapy", "Switch to high-frequency oscillatory ventilation for rescue oxygenation", "Trial inhaled nitric oxide and further proning cycles before deciding on ECMO", "Initiate venoarterial ECMO because of concurrent vasopressor use"], "answer": "B", "answer_index": 1, "explanation": "She has severe ARDS with PaO2/FiO2 <80 despite optimal lung-protective ventilation, high PEEP, paralysis, and proning-meeting criteria for VV-ECMO in an experienced center. Further escalation of ventilator settings or oscillatory ventilation adds risk with limited additional benefit. Low-dose vasopressor does not mandate VA-ECMO; VV-ECMO is appropriate when cardiac function is adequate and shock is not predominant.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nThe clinical vignette describes a patient with severe ARDS (P/F ratio < 80) due to influenza pneumonia who remains hypoxemic despite optimal conventional management (lung-protective ventilation, high PEEP, neuromuscular blockade, and prone positioning). This clinical picture meets the inclusion criteria for the EOLIA trial and standard guidelines for considering venovenous (VV) ECMO (e.g., P/F < 80 mmHg for > 6 hours). \\n\\nOption B is the best answer as the patient has failed less invasive rescue therapies. Option C (HFOV) is incorrect based on the OSCILLATE and OSCAR trials, which showed no benefit or harm. Option E (VA-ECMO) is incorrect because the patient has isolated respiratory failure with preserved perfusion (low lactate, low-dose vasopressors), indicating VV-ECMO is sufficient. Option D (iNO) provides only transient oxygenation improvement without mortality benefit and should not delay ECMO in a qualifying patient. Option A is unlikely to succeed and risks barotrauma. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nThe clinical vignette describes a patient with severe ARDS (P/F ratio < 80) due to influenza pneumonia who remains hypoxemic despite optimal conventional management (lung-protective ventilation, high PEEP, neuromuscular blockade, and prone positioning). This clinical picture meets the inclusion criteria for the EOLIA trial and standard guidelines for considering venovenous (VV) ECMO (e.g., P/F < 80 mmHg for > 6 hours). \n\nOption B is the best answer as the patient has failed less invasive rescue therapies. Option C (HFOV) is incorrect based on the OSCILLATE and OSCAR trials, which showed no benefit or harm. Option E (VA-ECMO) is incorrect because the patient has isolated respiratory failure with preserved perfusion (low lactate, low-dose vasopressors), indicating VV-ECMO is sufficient. Option D (iNO) provides only transient oxygenation improvement without mortality benefit and should not delay ECMO in a qualifying patient. Option A is unlikely to succeed and risks barotrauma. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-010", "question": "A 10-year-old boy with a history of intermittent asthma presents with 3 weeks of fever, weight loss, night sweats, and progressive joint pains. Exam: non-blanching palpable purpura on lower extremities, mononeuritis multiplex with foot drop, and hypertension (130/86 mmHg). No asthma exacerbation. Labs: ESR 90 mm/hr, CRP 12 mg/dL, creatinine 1.1 mg/dL, urinalysis with 1+ protein and few RBCs, hepatitis B surface antigen positive, high HBV DNA titer, negative ANCA. CT angiography: multiple microaneurysms in mesenteric and renal arteries. What is the most appropriate initial treatment strategy?", "options": ["High-dose corticosteroids plus cyclophosphamide without antiviral therapy", "Start entecavir and delay immunosuppression until HBV viral load is suppressed", "High-dose corticosteroids plus plasma exchange and antiviral therapy", "Rituximab with low-dose steroids and entecavir prophylaxis", "Plasma exchange and entecavir only, avoiding immunosuppression"], "answer": "C", "answer_index": 2, "explanation": "He has HBV-associated polyarteritis nodosa with medium-vessel aneurysms and high viral load. Management requires control of both vasculitis and viral replication: short-course high-dose steroids with plasma exchange and concurrent antiviral therapy is recommended. Prolonged cyclophosphamide without antivirals worsens HBV; antivirals alone are insufficient in active PAN; rituximab is less established in HBV-PAN.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The patient presents with classic Hepatitis B-associated Polyarteritis Nodosa (HBV-PAN), evidenced by systemic symptoms, mononeuritis multiplex, renal microaneurysms, hypertension, and HBsAg positivity with negative ANCA. The management of HBV-PAN is a high-yield board topic because it differs fundamentally from idiopathic PAN. While idiopathic PAN is treated with prolonged immunosuppression (corticosteroids + cyclophosphamide), HBV-PAN requires clearing the antigen source and removing immune complexes. The standard regimen for severe HBV-PAN involves antiviral therapy (e.g., entecavir), plasma exchange (to remove immune complexes), and a short course of corticosteroids to control acute inflammation. Prolonged cyclophosphamide (Option A) is contraindicated as it enhances viral replication and liver injury. Option B is insufficient for severe, organ-threatening vasculitis (aneurysms, foot drop). Option D is appropriate for ANCA-associated vasculitis, not PAN. Option C accurately reflects the consensus guideline approach for this specific entity. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The patient presents with classic Hepatitis B-associated Polyarteritis Nodosa (HBV-PAN), evidenced by systemic symptoms, mononeuritis multiplex, renal microaneurysms, hypertension, and HBsAg positivity with negative ANCA. The management of HBV-PAN is a high-yield board topic because it differs fundamentally from idiopathic PAN. While idiopathic PAN is treated with prolonged immunosuppression (corticosteroids + cyclophosphamide), HBV-PAN requires clearing the antigen source and removing immune complexes. The standard regimen for severe HBV-PAN involves antiviral therapy (e.g., entecavir), plasma exchange (to remove immune complexes), and a short course of corticosteroids to control acute inflammation. Prolonged cyclophosphamide (Option A) is contraindicated as it enhances viral replication and liver injury. Option B is insufficient for severe, organ-threatening vasculitis (aneurysms, foot drop). Option D is appropriate for ANCA-associated vasculitis, not PAN. Option C accurately reflects the consensus guideline approach for this specific entity. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]